Molecular detection of FUS-CREB3L2 fusion transcripts in low-grade fibromyxoid sarcoma using formalin-fixed, paraffin-embedded tissue specimens

Atsuji Matsuyama, Masanori Hisaoka, Shohei Shimajiri, Tomayoshi Hayashi, Tetsuo Imamura, Tsuyoshi Ishida, Masaharu Fukunaga, Toshiyuki Fukuhara, Hiroshi Minato, Takashi Nakajima, Suguru Yonezawa, Makoto Kuroda, Fumio Yamasaki, Satoshi Toyoshima, Hiroshi Hashimoto

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

A diagnosis of low-grade fibromyxoid sarcoma (LGFMS) remains problematic because of its bland-looking histologic features that can be potentially confused with other benign or low-grade fibromyxoid lesions. Recent cytogenetic and molecular analyses have shown that most LGFMSs have a characteristic chromosomal abnormality, t(7;16)(q33;p11), resulting in the FUS-CREB3L2 fusion gene. However, such assays have only rarely been used to analyze formalin-fixed, paraffin-embedded tumor samples. In the present study, we conducted a reverse transcription-polymerase chain reaction assay to detect the FUS-CREB3L2 fusion transcripts using formalin-fixed, paraffin-embedded tumor tissue specimens from 16 LGFMSs including 3 cases with giant collagen rosettes. The primers were newly designed to specifically amplify most of the junctional regions of the FUS-CREB3L2 fusion gene transcripts previously reported. The FUS-CREB3L2 fusion gene transcripts were detected in 14/16 (88%) cases of LGFMS. A nucleotide sequence analysis of the PCR products revealed that different portions of the FUS exon 6 or 7 were fused with various sites of the CREB3L2 exon 5, resulting in 12 different nucleotide sequences. We also tested a primer set to detect the FUS-CREB3L1 fusion transcript, which is a rare variant of the gene fusion in LGFMS, although no PCR products were identified in any case. The FUS-CREB3L2 fusion transcripts were not detected in any of the 123 other soft-tissue tumors, including desmoid-type fibromatoses, myxofibrosarcomas, soft-tissue perineuriomas, and congenital or adult fibrosarcomas. These data suggest that our reverse transcription-polymerase chain reaction assay is a reliable method to detect FUS-CREB3L2, which can thus help in accurately diagnosing LGFMS.

Original languageEnglish
Pages (from-to)1077-1084
Number of pages8
JournalAmerican Journal of Surgical Pathology
Volume30
Issue number9
DOIs
Publication statusPublished - 01-09-2006

All Science Journal Classification (ASJC) codes

  • Anatomy
  • Surgery
  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Molecular detection of FUS-CREB3L2 fusion transcripts in low-grade fibromyxoid sarcoma using formalin-fixed, paraffin-embedded tissue specimens'. Together they form a unique fingerprint.

  • Cite this

    Matsuyama, A., Hisaoka, M., Shimajiri, S., Hayashi, T., Imamura, T., Ishida, T., Fukunaga, M., Fukuhara, T., Minato, H., Nakajima, T., Yonezawa, S., Kuroda, M., Yamasaki, F., Toyoshima, S., & Hashimoto, H. (2006). Molecular detection of FUS-CREB3L2 fusion transcripts in low-grade fibromyxoid sarcoma using formalin-fixed, paraffin-embedded tissue specimens. American Journal of Surgical Pathology, 30(9), 1077-1084. https://doi.org/10.1097/01.pas.0000209830.24230.1f